Aran Maree, M.D., who served as Chief Medical Officer since 2024, appointed Chief Executive Officer and Board Member succeeding Mark Alles who will continue as Board Chairman

阿兰·马里医学博士自2024年起担任首席医疗官，被任命为首席执行官及董事会成员，接替马克·阿尔斯，后者将继续担任董事会主席。

LOS ANGELES

洛杉矶

,

，

May 7, 2026

2026年5月7日

/PRNewswire/ -- TORL BioTherapeutics LLC (TORL), a clinical stage oncology focused biotechnology company, today announced a leadership transition to position the Company for its next phase of growth. Effective as of May 1, 2026, Aran Maree, M.D., is appointed Chief Executive Officer (CEO) and Board Member.

/PRNewswire/ -- TORL BioTherapeutics LLC（TORL），一家专注于临床阶段肿瘤学的生物技术公司，今天宣布了一项领导层过渡，以推动公司进入下一个增长阶段。自2026年5月1日起，阿兰·马里医学博士被任命为首席执行官（CEO）兼董事会成员。

Dr. Maree succeeds Mark Alles, who will continue to support the Company as Chairman of the Board..

马里博士接替了马克·阿勒斯，后者将继续作为董事会主席支持公司。

'TORL was founded to discover, develop, and commercialize first- and best-in-class cancer therapeutics. Given Aran's highly successful, multi-decade industry career, and the leadership he has demonstrated throughout his tenure as TORL's first Chief Medical Officer, the Board and I are confident he has the experience, insight, and passion to continue to guide TORL through and beyond this critical next phase of clinical milestones,' said .

TORL 成立的宗旨是发现、开发和商业化首屈一指和同类最佳的癌症治疗药物。鉴于阿兰在其长达数十年的行业生涯中取得了极高的成就，并且在他担任 TORL 首任首席医学官期间展现出了卓越的领导才能，董事会和我相信他拥有继续引领 TORL 度过并超越这一关键的下一阶段临床里程碑的经验、洞察力和热情。

Mark J. Alles, Chairman of TORL BioTherapeutics

马克·J·阿莱斯，TORL生物治疗公司董事长

. 'His appointment reflects a carefully planned leadership transition designed to position TORL for growth and operational scale, and I look forward to continuing to work with Aran and the rest of the TORL team to improve patient outcomes.'

“他的任命反映了一项精心策划的领导层过渡计划，旨在为TORL实现增长和运营规模定位，我期待继续与Aran及TORL团队的其他成员合作，以改善患者的治疗效果。”

Dr. Maree joined TORL in October 2024 as Chief Medical Officer (CMO). In that role, he led the clinical advancement of TORL's first-in-class Claudin 6 (CLDN6)-targeted antibody drug conjugate (ADC) ixotatug vedotin (Ixo-V; TORL-1-23), accelerating global enrollment in the registrational Phase 2 study,  CATALINA-2, in platinum-resistant ovarian cancer (PROC), and expanding Ixo-V clinical development beyond PROC.

Maree博士于2024年10月加入TORL，担任首席医疗官（CMO）。在此职位上，他领导了TORL首创的Claudin 6（CLDN6）靶向抗体药物偶联物（ADC）ixotatug vedotin（Ixo-V；TORL-1-23）的临床进展，推动了关键性二期研究CATALINA-2在铂耐药卵巢癌（PROC）中的全球患者招募，并将Ixo-V的临床开发扩展至PROC之外。

In collaboration with our discovery partners at UCLA, Dr. Maree has led TORL's development of multiple Investigational New Drug applications (INDs) across its differentiated early portfolio. These include TORL's first hematology asset, which is now in Phase 1, and accelerating IND-enabling work for TORL's next wave of programs..

与加州大学洛杉矶分校的发现合作伙伴合作，马里博士领导了TORL在多个研究性新药申请（IND）方面的工作，涉及其差异化的早期产品组合。这些包括TORL的首个血液学资产，目前已进入第一阶段，并加速推进TORL下一波项目的IND相关工作。

'I am honored to step into the CEO role with the support of Mark Alles and the TORL Board as we advance Ixo-V toward its first regulatory filings and build out our early-stage pipeline,' said

“在Mark Alles和TORL董事会的支持下，我深感荣幸能够担任首席执行官一职，带领Ixo-V迈向首次监管申报，并推进我们早期阶段的研发管线建设，”他表示。

Aran Maree, M.D., Chief Executive Officer

阿兰·马里，医学博士，首席执行官

. 'TORL exists to develop antibody-based therapies that meaningfully improve the lives of people with cancer. With our expanding leadership team, we are well-positioned to deliver on our mission.'

“TORL 的宗旨是开发基于抗体的疗法，显著改善癌症患者的生活。随着我们领导团队的不断壮大，我们有能力实现自己的使命。”

Dr. Maree's appointment is part of a broader strategic plan to strengthen TORL's leadership team and enhance governance as the Company progresses toward late-stage development and potential commercialization. A search for TORL's next CMO is now underway. Earlier in 2026, and as part of this succession plan, TORL appointed multiple proven leaders into new roles designed to further prepare the organization for future growth.

Maree博士的任命是TORL更广泛战略计划的一部分，旨在加强TORL的领导团队并提升公司治理水平，以支持公司向后期开发和潜在商业化迈进。目前，TORL正在寻找下一任首席医学官（CMO）。在2026年初，作为该继任计划的一部分，TORL任命了多位经验丰富的新领导者担任新职位，以进一步为组织未来的发展做好准备。

Together, TORL's leadership team has decades of experience building biotechnology companies and developing practice-changing therapies for patients with serious unmet medical needs. Newly appointed executive team members include:.

TORL的领导团队共同拥有数十年构建生物技术公司和为具有严重未满足医疗需求的患者开发改变实践的疗法的经验。新任命的执行团队成员包括：。

Christine Loggins, MBA

克里斯汀·洛金斯，工商管理硕士

- Chief Operating Officer

- 首席运营官

Steve Ritland, Ph.D.

史蒂夫·里特兰德，博士

- Chief Scientific Officer

- 首席科学官

Vince Ruiz, J.D.

文斯·鲁伊斯，法学博士

-

-

General Counsel

总法律顾问

To date, TORL has raised more than $450M from leading global biotechnology investors. Beyond its lead CLDN6 program, the Company's pipeline includes an ADC targeting Delta-like Non-canonical Notch Ligand 1 (DLK1), along with additional undisclosed targets spanning solid tumors and hematologic malignancies..

迄今为止，TORL已经从全球领先的生物技术投资者那里筹集了超过4.5亿美元。除了其主要的CLDN6项目外，该公司的产品管线还包括一款靶向Delta-like非经典Notch配体1（DLK1）的抗体药物偶联物（ADC），以及涵盖实体瘤和血液恶性肿瘤的其他未披露靶点。

About Claudin 6

关于Claudin 6

Claudin 6 (CLDN6) is overexpressed in several cancers with limited to no detectable expression observed in normal tissues, making it an ideal target for ADC development. CLDN6 is a transmembrane protein and member of a family of proteins important for cell-to-cell connectivity in normal tissues. CLDN6 expression normally occurs during embryonic and fetal development but not in adult tissues.

Claudin 6 (CLDN6) 在多种癌症中过度表达，而在正常组织中几乎检测不到表达，这使其成为ADC开发的理想靶点。CLDN6 是一种跨膜蛋白，属于在正常组织中对细胞间连接起重要作用的蛋白家族成员。CLDN6 的表达通常发生在胚胎和胎儿发育期间，而不在成人组织中。

Overexpression of CLDN6 occurs in specific malignancies and has been implicated in the pathogenesis of certain cancers including ovarian, non-small cell lung, endometrial and testicular malignancies. High expression correlates with shortened survival outcomes for patients with ovarian cancer..

特定恶性肿瘤中会出现CLDN6的过表达，并且其与某些癌症的发病机制有关，包括卵巢癌、非小细胞肺癌、子宫内膜癌和睾丸恶性肿瘤。高表达与卵巢癌患者的生存期缩短相关。

About Ixotatug Vedotin (Ixo-V; TORL-1-23)

关于伊索塔图格·维多汀（Ixo-V；TORL-1-23）

Ixotatug vedotin is a first- and potentially best-in-class clinical-stage ADC for the treatment of CLDN6+ solid tumors. Ixotatug vedotin has received Fast Track Designation from the U.S. Food and Drug Administration. TORL BioTherapeutics is currently enrolling the pivotal Phase 2 CATALINA-2 study of ixotatug vedotin in women with CLDN6+ PROC.

伊克索塔图格·维多汀是一种首创新药，且可能是同类最佳的临床阶段抗体药物偶联物（ADC），用于治疗CLDN6阳性实体瘤。伊克索塔图格·维多汀已获得美国食品药品监督管理局（FDA）的快速通道资格。TORL生物治疗公司目前正在招募关键的二期CATALINA-2研究，评估伊克索塔图格·维多汀在CLDN6阳性PROC女性患者中的疗效。

Further details can be found at .

更多信息可以在这里找到。

https://clinicaltrials.gov/study/NCT06690775

https://clinicaltrials.gov/study/NCT06690775

.

。

About CATALINA-2

关于CATALINA-2

CATALINA-2 is a global, randomized, open-label Phase 2 study of novel CLDN6-targeted ADC ixotatug vedotin in women with CLDN6+ PROC who have received one to three prior lines of therapy. The primary endpoint is objective response rate (ORR) per RECIST v1.1 by blinded independent central review. Secondary endpoints consist of duration of response, ORR by investigator assessment, progression-free survival, overall survival and safety.

CATALINA-2 是一项全球性、随机、开放标签的二期临床研究，评估新型靶向CLDN6的抗体药物偶联物 ixotatug vedotin 在接受过一至三线治疗的CLDN6阳性PROC女性患者中的疗效。主要终点是由盲态独立中心审查根据RECIST v1.1标准评估的客观缓解率（ORR）。次要终点包括缓解持续时间、研究者评估的客观缓解率、无进展生存期、总生存期以及安全性。

Further details can be found at .

更多信息请见 。

https://clinicaltrials.gov/study/NCT06690775

https://clinicaltrials.gov/study/NCT06690775

.

。

About TORL BioTherapeutics LLC

关于TORL生物治疗有限责任公司

TORL is a clinical-stage biopharmaceutical company developing new antibodies, both monoclonal antibodies and ADCs, with the goal of transforming the lives of patients challenged with a variety of human malignancies. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for new, promising and novel cancer targets..

TORL是一家临床阶段的生物制药公司，致力于开发新的抗体，包括单克隆抗体和ADC，旨在改变面临各种人类恶性肿瘤挑战的患者的生活。通过与加州大学洛杉矶分校Slamon研究实验室的战略合作，TORL拥有针对全新、前景广阔且独特的癌症靶点的大型生物药物项目的独家开发和商业权利。

SOURCE TORL Biotherapeutics LLC

来源：TORL 生物治疗有限公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示